Short Interest in International Stem Cell Corp. (OTCMKTS:ISCO) Drops By 51.1%

International Stem Cell Corp. (OTCMKTS:ISCO) was the target of a significant drop in short interest in the month of June. As of June 30th, there was short interest totaling 6,699 shares, a drop of 51.1% from the June 15th total of 13,705 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average trading volume of 7,053 shares, the days-to-cover ratio is currently 0.9 days.

International Stem Cell Price Performance

Shares of OTCMKTS ISCO traded up $0.06 during mid-day trading on Thursday, reaching $0.23. The company’s stock had a trading volume of 65,955 shares, compared to its average volume of 7,084. The firm has a market capitalization of $1.82 million, a PE ratio of -3.80 and a beta of -0.01. The stock has a fifty day moving average of $0.17 and a two-hundred day moving average of $0.16. International Stem Cell has a 52 week low of $0.12 and a 52 week high of $0.23.

International Stem Cell (OTCMKTS:ISCO) last issued its earnings results on Thursday, May 14th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $2.32 million during the quarter.

International Stem Cell Company Profile

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.